Gabriele Buda

2.4k total citations
89 papers, 908 citations indexed

About

Gabriele Buda is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Gabriele Buda has authored 89 papers receiving a total of 908 indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 43 papers in Hematology and 39 papers in Molecular Biology. Recurrent topics in Gabriele Buda's work include Multiple Myeloma Research and Treatments (33 papers), Peptidase Inhibition and Analysis (20 papers) and Chronic Lymphocytic Leukemia Research (16 papers). Gabriele Buda is often cited by papers focused on Multiple Myeloma Research and Treatments (33 papers), Peptidase Inhibition and Analysis (20 papers) and Chronic Lymphocytic Leukemia Research (16 papers). Gabriele Buda collaborates with scholars based in Italy, United States and Germany. Gabriele Buda's co-authors include Mario Petrini, Sara Galimberti, Enrico Orciuolo, Giuseppe Vergaro, Giovanni Carulli, Fortunato Morabito, Angela Pucci, Roberto Barale, Alessandro Di Martino and Valentina Maggini and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Annals of Oncology.

In The Last Decade

Gabriele Buda

84 papers receiving 891 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gabriele Buda Italy 17 389 352 236 174 165 89 908
Michishi Tsukano Japan 17 347 0.9× 125 0.4× 202 0.9× 100 0.6× 95 0.6× 40 1.1k
Yannick Degboé France 20 231 0.6× 152 0.4× 214 0.9× 115 0.7× 110 0.7× 70 1.1k
Seongseok Yun United States 18 306 0.8× 464 1.3× 344 1.5× 248 1.4× 206 1.2× 79 1.1k
Muna Qayed United States 15 280 0.7× 315 0.9× 207 0.9× 192 1.1× 47 0.3× 80 886
Piyanka Chandra United States 12 438 1.1× 176 0.5× 115 0.5× 87 0.5× 61 0.4× 13 1.6k
Monika Prochorec‐Sobieszek Poland 21 320 0.8× 297 0.8× 128 0.5× 172 1.0× 320 1.9× 106 1.2k
Young‐Woo Jeon South Korea 20 299 0.8× 430 1.2× 770 3.3× 287 1.6× 207 1.3× 146 1.4k
Dehui Zou China 20 519 1.3× 666 1.9× 554 2.3× 364 2.1× 417 2.5× 162 1.4k
Yasuo Hirayama Japan 15 332 0.9× 355 1.0× 705 3.0× 255 1.5× 107 0.6× 61 1.3k
Po‐Min Chen Taiwan 17 359 0.9× 461 1.3× 265 1.1× 166 1.0× 218 1.3× 80 1.2k

Countries citing papers authored by Gabriele Buda

Since Specialization
Citations

This map shows the geographic impact of Gabriele Buda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriele Buda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriele Buda more than expected).

Fields of papers citing papers by Gabriele Buda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriele Buda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriele Buda. The network helps show where Gabriele Buda may publish in the future.

Co-authorship network of co-authors of Gabriele Buda

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriele Buda. A scholar is included among the top collaborators of Gabriele Buda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriele Buda. Gabriele Buda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Genovesi, Dario, Giuseppe Vergaro, Assuero Giorgetti, et al.. (2024). [18F]‐florbetaben PET/CT is sensitive for cardiac AL amyloidosis. European Journal of Clinical Investigation. 54(10). e14270–e14270. 1 indexed citations
3.
Galimberti, Sara, et al.. (2024). Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis. Hematological Oncology. 42(3). e3270–e3270. 2 indexed citations
4.
Vergaro, Giuseppe, Dario Genovesi, Vincenzo Castiglione, et al.. (2024). Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis. European Heart Journal - Cardiovascular Imaging. 26(3). 500–508. 5 indexed citations
5.
Aimo, Alberto, Giuseppe Vergaro, Vincenzo Castiglione, et al.. (2024). Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study. European Journal of Preventive Cardiology. 31(11). 1410–1417. 9 indexed citations
6.
Vergaro, Giuseppe, Alberto Aimo, Claudio Rapezzi, et al.. (2022). Atrial amyloidosis: mechanisms and clinical manifestations. European Journal of Heart Failure. 24(11). 2019–2028. 47 indexed citations
7.
Emdin, Michele, Federico Perfetto, Alberto Aimo, et al.. (2021). Percorso clinico-assistenziale in rete per la diagnosi e la gestione del paziente con amiloidosi cardiaca. Documento di consenso ANMCO Toscana e SIC Tosco-Umbra. Giornale italiano di cardiologia. 22(8). 621–634.
8.
Barachini, Serena, Marina Montali, Vittoria Carnicelli, et al.. (2021). Mesangiogenic Progenitor Cells Are Tissue Specific and Cannot Be Isolated From Adipose Tissue or Umbilical Cord Blood. Frontiers in Cell and Developmental Biology. 9. 669381–669381. 2 indexed citations
9.
Aimo, Alberto, Gabriele Buda, Marianna Fontana, et al.. (2018). Therapies for cardiac light chain amyloidosis: An update. International Journal of Cardiology. 271. 152–160. 28 indexed citations
10.
Iovino, Lorenzo, Francesco Mazziotta, Giovanni Carulli, et al.. (2018). High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naïve lymphocytes and prevents TTV reactivation. Leukemia Research. 70. 20–24. 40 indexed citations
11.
Fontanelli, Giulia, F Caracciolo, E. Benedetti, et al.. (2013). Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 14(1). e13–e17. 2 indexed citations
12.
Bhatta, Dwij Raj, et al.. (2011). Extended spectrum â-lactamase producing multidrug resistant clinical bacterial isolates at National Public Health Laboratory, Nepal.. PubMed. 13(1). 34–8. 15 indexed citations
13.
Buda, Gabriele, Giovanni Carulli, Enrico Orciuolo, et al.. (2010). CD23 expression in plasma cell leukaemia. Acta Haematologica. 150(6). 724–725.
14.
15.
Cervetti, Giulia, Sara Galimberti, Gabriele Buda, et al.. (2009). Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL).Ann Oncol. 2010 Apr;21(4):851-4. Epub 2009 Oct 13.. Annals of Oncology. 21(4). 851–854. 3 indexed citations
16.
Buda, Gabriele, Alessandro Di Martino, Valentina Maggini, et al.. (2009). MDR1 C3435T Polymorphism Indicates a Different Outcome in Advanced Multiple Myeloma. Acta Haematologica. 122(1). 42–45. 9 indexed citations
17.
Maggini, Valentina, Gabriele Buda, Alessandro Di Martino, et al.. (2008). MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenetics and Genomics. 18(5). 383–389. 26 indexed citations
18.
Sacchi, Stefano, Luigi Marcheselli, Alessia Bari, et al.. (2008). Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica. 93(3). 398–404. 65 indexed citations
19.
Galimberti, Sara, Nadia Cecconi, Giulia Cervetti, et al.. (2007). EFFICACY OF FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (FCR) REGIMEN FOL-LOWED BY ALEMTUZUMAB AS IN VIVO PURGING TOOL FOR PATIENTS WITH ADVANCEDCHRONIC LYMPHOCYTIC LEUKEMIA. Haematologica. 92. 24–24. 2 indexed citations
20.
Trombi, Luisa, Letizia Mattii, Simone Pacini, et al.. (2007). Human autologous plasma‐derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. Journal of Orthopaedic Research®. 26(2). 176–183. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michishi Tsukano Breakdown of academic impact, for papers by Yannick Degboé Breakdown of academic impact, for papers by Seongseok Yun Breakdown of academic impact, for papers by Muna Qayed Breakdown of academic impact, for papers by Piyanka Chandra Breakdown of academic impact, for papers by Monika Prochorec‐Sobieszek Breakdown of academic impact, for papers by Young‐Woo Jeon Breakdown of academic impact, for papers by Dehui Zou Breakdown of academic impact, for papers by Yasuo Hirayama Breakdown of academic impact, for papers by Po‐Min Chen
Rankless by CCL
2026